drugset / Trial / NCT00364260

A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects.

NCT00364260

Phase 3 Completed 172 enrolled Janssen-Ortho Inc., Canada
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to determine if using Eprex, to maintain hemoglobin within the normal range, will prevent or delay the progression of left ventricular mass growth.

Timeline

Start
1997-12
Primary completion
Completion
2003-08

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 2000 iu Subcutaneous
Subject epoetin alfa Protein / enzyme biologic 3000 iu Subcutaneous

Indications